PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Tuesday evening that the Food and Drug Administration (FDA), the American health authority, had approved Dupixent for the treatment of patients aged six months to five years with Moderate to severe atopic dermatitis not controlled by topical prescription medications or for which these medications are not recommended.
Atopic dermatitis is a chronic inflammatory skin disease that can be debilitating.
“Dupixent is the first and only biologic drug approved for the treatment of moderate to severe atopic dermatitis from infancy through adulthood,” Sanofi said in a statement.
Dupixent is approved in several countries for the treatment of atopic dermatitis, asthma and nasal polyposis or eosinophilic esophagitis in certain categories of patients in different age groups.
Dupixent is currently approved for these indications in the United States and for one or more of these indications in the European Union, Japan and in more than 60 countries. “More than 400,000 patients worldwide have already been treated with this drug,” Sanofi said.
A trade name for dupilumab, Dupixent is jointly developed by Sanofi and Regeneron under a global collaboration agreement. At the end of March, Sanofi increased its turnover target for Dupixent to more than 13 billion euros at cruising speed.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
June 08, 2022 01:01 ET (05:01 GMT)